First and Second Line Antibiotics for Strep Throat
First-Line Treatment
Amoxicillin 500 mg orally twice daily for 10 days is the first-line treatment for strep throat in adults, while penicillin remains equally acceptable. 1 Both agents demonstrate proven efficacy, narrow spectrum activity, excellent safety profiles, modest cost, and critically—no documented resistance anywhere in the world. 1
- For pediatric patients over 3 months of age, amoxicillin 20-45 mg/kg/day divided every 8-12 hours for 10 days is recommended. 2
- The full 10-day course is essential to achieve maximal pharyngeal eradication of Group A Streptococcus and prevent acute rheumatic fever, even though symptoms typically resolve within 3-4 days. 3, 1
Second-Line Treatment: For Penicillin-Allergic Patients
Non-Immediate (Non-Anaphylactic) Penicillin Allergy
First-generation cephalosporins are the preferred second-line alternatives for patients with non-immediate penicillin allergies. 3, 1
- Cephalexin 500 mg orally twice daily for 10 days (adults) or 20 mg/kg per dose twice daily for 10 days (pediatrics, maximum 500 mg/dose) is the specific recommendation. 3, 1
- Cefadroxil 30 mg/kg once daily for 10 days is an acceptable alternative with once-daily dosing convenience. 3
- Cross-reactivity risk is only 0.1% in patients with non-severe, delayed penicillin reactions, making first-generation cephalosporins very safe in this population. 3
- These agents have strong, high-quality evidence supporting superior or equivalent efficacy compared to penicillin. 3
Immediate/Anaphylactic Penicillin Allergy
For patients with immediate hypersensitivity reactions (anaphylaxis, angioedema, urticaria within 1 hour), all beta-lactam antibiotics including cephalosporins must be avoided due to up to 10% cross-reactivity risk. 3, 1
Clindamycin is the preferred choice for immediate penicillin allergy:
- Clindamycin 300 mg orally three times daily for 10 days (adults) or 7 mg/kg per dose three times daily for 10 days (pediatrics, maximum 300 mg/dose). 3, 1
- Clindamycin has strong, moderate-quality evidence with approximately 1% resistance rate among Group A Streptococcus in the United States. 3, 1
- It demonstrates high efficacy even in chronic streptococcal carriers who have failed penicillin treatment. 3
Macrolides are acceptable alternatives but less preferred:
- Azithromycin 500 mg once daily for 5 days (adults) or 12 mg/kg once daily for 5 days (pediatrics, maximum 500 mg). 3, 4
- Azithromycin is the only antibiotic requiring just 5 days due to its prolonged tissue half-life. 3, 4
- Clarithromycin 250 mg twice daily for 10 days (adults) or 7.5 mg/kg per dose twice daily for 10 days (pediatrics, maximum 250 mg/dose). 3
- Macrolide resistance is 5-8% in the United States and varies geographically, making clindamycin more reliable. 3, 1
Critical Treatment Algorithm
- No penicillin allergy → Amoxicillin 500 mg twice daily × 10 days 1
- Non-immediate penicillin allergy (delayed rash, no anaphylaxis) → Cephalexin 500 mg twice daily × 10 days 3, 1
- Immediate/anaphylactic penicillin allergy → Clindamycin 300 mg three times daily × 10 days 3, 1
- Cannot tolerate clindamycin or high local macrolide resistance → Consider azithromycin 500 mg daily × 5 days with awareness of resistance patterns 3
Common Pitfalls to Avoid
- Never shorten antibiotic courses below 10 days (except azithromycin's 5-day regimen), as this dramatically increases treatment failure rates and acute rheumatic fever risk. 3, 1
- Do not assume all penicillin-allergic patients cannot receive cephalosporins—only those with immediate/anaphylactic reactions should avoid them. 3, 1
- Do not prescribe broad-spectrum cephalosporins (cefdinir, cefpodoxime, cefuroxime) when narrow-spectrum first-generation agents are appropriate, as they are more expensive and select for resistant flora. 3
- Be aware of local macrolide resistance patterns before prescribing azithromycin or clarithromycin, as resistance can exceed 10% in some geographic areas. 3
- Never use trimethoprim-sulfamethoxazole (Bactrim) for strep throat due to 50% resistance rates and lack of efficacy against Group A Streptococcus. 3